Nuvation Bio
NUVB
182 hedge funds and large institutions have $439M invested in Nuvation Bio in 2025 Q2 according to their latest regulatory filings, with 43 funds opening new positions, 80 increasing their positions, 30 reducing their positions, and 20 closing their positions.
268% more call options, than puts
Call options by funds: $4.67M | Put options by funds: $1.27M
167% more repeat investments, than reductions
Existing positions increased: 80 | Existing positions reduced: 30
115% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 20
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
20% more capital invested
Capital invested by funds: $365M → $439M (+$74.2M)
13% more funds holding
Funds holding: 161 → 182 (+21)
4.64% more ownership
Funds ownership: 61.4% → 66.04% (+4.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$15.1M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$7.14M |
| 3 |
Millennium Management
New York
|
+$3.35M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
+$2.15M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
+$2.09M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
Rosalind Advisors
Toronto,
Ontario, Canada
|
-$4.31M |
| 2 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
-$4.23M |
| 3 |
Morgan Stanley
New York
|
-$1.58M |
| 4 |
WC
Wexford Capital
West Palm Beach,
Florida
|
-$1.44M |
| 5 |
AIC
AWM Investment Company
New York
|
-$1.14M |
NUVB Hedge Fund Activity: Q2 2025 in Review
182 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Nuvation Bio (NUVB) for Q2 2025, worth a combined $439M — up 20% from $365M a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new NUVB positions and 20 closed out — a net gain of 23 holders — while 80 added to existing stakes and 30 trimmed.
The largest buyer was BlackRock, adding an estimated $15.1M. The largest seller was Rosalind Advisors, exiting entirely with an estimated $4.31M sold.
- 182 institutional investors held Nuvation Bio (NUVB) as of Q2 2025, up from 161 in Q1 2025.
- Funds reported $439M of Nuvation Bio stock for Q2 2025, up 20% quarter-over-quarter.
- 43 funds opened new Nuvation Bio positions in Q2 2025 and 20 closed out, a net change of +23 holders.
- The largest Nuvation Bio buyer in Q2 2025 was BlackRock, an estimated $15.1M added.
- The largest Nuvation Bio seller in Q2 2025 was Rosalind Advisors, an estimated $4.31M sold.
Based on aggregated 13F filings for Q2 2025.